Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01682928 · ClinicalTrials.gov registry record · NA

Hydrotherapy for the Reversal of Oligohydramnios

A NA study, sponsored by Pediatrix.

Terminated
Registry status
NA
Development phase
4
Enrollment target

NCT01682928 is a NA study that was terminated before completion, run by Pediatrix. The registered enrollment target is 4 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01682928, a NA study, was terminated before completion, sponsored by Pediatrix.

TERMINATED
Registry status
NA
Development phase
4 participants
Enrollment target

Study Summary

OBJECTIVE: To assess the efficacy of subtotal immersion therapy as an option to improve maternal intravascular volume thereby improving both maternal and fetal hemodynamic status with reversal of oligohydramnios. This will be measured utilizing the Amniotic Fluid Volume (AFV) as the primary outcome. Secondary outcomes will be measured using Fetal Doppler Studies, Maternal vital signs (Blood Pressure, Pulse Pressure, Weight, Pulse) and input/output. HYPOTHESIS: Oligohydramnios, secondary to depleted maternal intravascular volume, can be reversed by improving feto- and uteroplacental perfusion with subtotal immersion therapy.

Interventions

  • DRUG IV/Oral Hydration and Bedrest
  • OTHER Hydrotherapy

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2012-08
Est. Completion 2014-12
Phase NA

Sponsor

Pediatrix

28 total trials

What the Registry Record Tells You About NCT01682928

The ClinicalTrials.gov registry entry for NCT01682928 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pediatrix, which has 28 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which IV/Oral Hydration and Bedrest is the first listed.

NCT01682928 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01682928 about?

NCT01682928 is a clinical study titled "Hydrotherapy for the Reversal of Oligohydramnios". OBJECTIVE: To assess the efficacy of subtotal immersion therapy as an option to improve maternal intravascular volume thereby improving both maternal and fetal hemodynamic status with reversal of oligohydramnios. This will be measured utilizing the Amniotic Fluid Volume (AFV) as the primary outcome....

What is the current status of trial NCT01682928?

This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2012-08. Estimated completion is 2014-12.

What interventions are being tested in trial NCT01682928?

The interventions under investigation include: IV/Oral Hydration and Bedrest (DRUG), Hydrotherapy (OTHER).

Who is sponsoring clinical trial NCT01682928?

This trial is sponsored by Pediatrix, which has 28 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.